Evidence map›Paper›PMID 34617068›Full record

Trial reportThe Lancet. Microbe2021

Radiological and functional evidence of the bronchial spread of tuberculosis: an observational analysis.

Ray Y Chen, Xiang Yu, Bronwyn Smith, Xin Liu, Jingcai Gao, Andreas H Diacon, Rodney Dawson, Michele Tameris, Hong Zhu, Yahong Qu and 13 more

Open access · goldAbstract readObservational StudyRandomized Controlled Trial
In one paragraph

Trial report in The Lancet. Microbe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. EANM/SNMMI guideline/procedure standard for [European journal of nuclear medicine and molecular imaging · 2025
    Guideline
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Candidate transmission survival genome ofProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  11. Article
  12. PET/CT guided tuberculosis treatment shortening: a randomized trial.medRxiv : the preprint server for health sciences · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 11 institutions in 5 countries.

Ray Y ChenTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Xiang YuTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Bronwyn SmithDST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Xin LiuHenan Provincial Chest Hospital, Zhengzhou, Henan, China.
Jingcai GaoSino-US Tuberculosis Collaborative Research Program, Zhengzhou, Henan, China.
Andreas H DiaconDepartment of Medicine, Stellenbosch University, Cape Town, South Africa.
Rodney DawsonDivision of Pulmonology, Department of Medicine, University of Cape Town Lung Institute, University of Cape Town, Cape Town, South Africa.
Michele TamerisSouth African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa.
Hong ZhuSino-US Tuberculosis Collaborative Research Program, Zhengzhou, Henan, China.
Yahong QuKaifeng City Institute of Tuberculosis Prevention and Control, Kaifeng, Henan, China.
Ruanqing ZhangXinxiang City Institute of Tuberculosis Prevention and Control, Xinxiang, Henan, China.
Shouguo PanZhongmu County Health and Epidemic Prevention Station, Zhongmu, Henan, China.
Xiaowei JinXinmi City Institute of Tuberculosis Prevention and Control, Xinmi, Henan, China.
Lisa C GoldfederTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Ying CaiTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Kriti AroraTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Jing WangClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Joel VincentTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Stephanus T MalherbeDST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Friedrich ThienemannDepartment of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Robert J WilkinsonWellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.
Gerhard WalzlDST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Clifton E BarryTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
National Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USStellenbosch University · ZAUniversity of Cape Town · ZAFrederick National Laboratory for Cancer Research · USHeilongjiang Center for Tuberculosis Control and Prevention · CNHenan Provincial Chest Hospital · CNKaifeng University · CNSouth African Medical Research Council · ZAThe Francis Crick Institute · GBUniversity Hospital of Zurich · CH

Funding

CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

backgroundDirect bronchial spread of tuberculosis was extensively described in pre-antibiotic human pathology literature but this description has been overlooked in the post-antibiotic era, in which most pathology data come from animal models that emphasise the granuloma. Modern techniques, such as [

methodsIn this observational analysis, we analysed data from PredictTB, an ongoing, prospective, randomised clinical trial that examined sequential baseline and week 4 FDG-PET-CT scans from participants successfully treated (sputum culture negative 18 months after enrolment) for drug-susceptible pulmonary tuberculosis in South Africa and China. Participants who were aged 18-75 years, GeneXpert MTB/RIF positive for tuberculosis and negative for rifampicin resistance, had not yet started tuberculosis treatment, had not been treated for active tuberculosis within the previous 3 years, and met basic safety laboratory criteria were included and participants with diabetes, HIV infection, or with extrapulmonary tuberculosis including pleural tuberculosis were excluded. Scans were assessed by two readers for the location of tuberculosis lesions (eg, cavities and consolidations), bronchial thickening patterns, and changes from baseline to week 4 of treatment.

findingsAmong the first 124 participants (enrolled from June 22, 2017, to Sept 27, 2018) who were successfully treated, 161 primarily apical cavitary lesions were identified at baseline. Bronchial thickening and inflammation linking non-cavitary consolidative lesions to cavities were observed in 121 (98%) of 124 participants' baseline PET-CT scans. After 4 weeks of treatment, 21 (17%) of 124 participants had new or expanding lesions linked to cavities via bronchial inflammation that were not present at baseline, particularly participants with two or more cavities at baseline and participants from South Africa.

interpretationIn participants with pulmonary tuberculosis who were subsequently cured, the location of cavitary and non-cavitary lesions at baseline and new lesions at week 4 of treatment suggest a cavitary origin of disease and bronchial spread through the lungs. Bronchial spread from cavities might play a larger role in the spread of pulmonary tuberculosis than has been appreciated. Elucidating cavity lesion dynamics and

fundingBill & Melinda Gates Foundation, European and Developing Countries Clinical Trials Partnership, China Ministry of Science and Technology, National Natural Science Foundation of China, and National Institutes of Health. TRANSLATIONS: For the Chinese, Afrikaans and Xhosa translations of the abstract see Supplementary Materials section.

Indexed as

HIV InfectionsTuberculosis, Lymph NodeTuberculosis, PulmonaryAnti-Bacterial AgentsFluorodeoxyglucose F18HumansInflammationPositron Emission Tomography Computed TomographyProspective StudiesRifampinSensitivity and SpecificityUnited StatesAnti-Bacterial AgentsFluorodeoxyglucose F18Rifampin

Identifiers

PMID34617068
PMCPMC8478663
OpenAlexW3181778966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.